Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomized, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial

Coates L.

Type

Journal article

Publisher

BMJ Publishing Group

Publication Date

2026-07-07T00:00:00+00:00

Permalink Close